Результаты поиска

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.

BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor venetoclax, is highly efficacious in chronic lymphocytic leukemia and has rapidly advanced to an approved standard of care in frontline and relapsed disease in combination with anti-CD20 monoclonal antibodies. In this context, tumour lysis syndrome and myelosuppression are the most commonly encountered toxicities and are readily manageable with established protocols. Venetoclax is active in oth

Belantamab mafodotin, bortezomib и dexamethasone для RRM в японской группе расширения фазы 3 DREAMM-7 суд.

Случайный, фазы 3 DREAMM-7 судебное разбирательствоNCT04246047) ранее продемонстрировали эффективность и безопасность белантамбового мафодотина, борцезомиба и дексаметазона (BVd) в сравнении с даратумумумабом, бортезомибом и дексаметазоном (DVd) у пациентов с повторной/реактивной множественной миеломой (RRMMM) и ≥ 1 предыдущая терапия. Результаты расширения Японии DREAMM-7, состоящая из 24 - пациенты, случайные для получения BVd (N = 10) или DVd (N = 14), представлены здесь. Средний показатель последующей деятельности 19.4 месяцев (дальность, 1.3-30.3). b) не было достигнуто выживаемости в усл

Совпадение в полном тексте источника
… With the increasing use of lenalidomide in Japanese patients in the first-line setting, more patients are likely to have lenalidomide-refractory disease, resulting in poor outcomes with retreatment at subsequent relapse [ 3 ]. …

Remineralization Rate of Lytic Lesions of the Spine in Multiple Myeloma Patients Undergoing Radiation Therapy.

Study DesignRetrospective cohort study.ObjectiveIn general, Multiple Myeloma (MM) patients are treated with systemic therapy including chemotherapy. Radiation therapy can have an important supportive role in the palliative management of MM-related osteolytic lesions. Our study aims to investigate the degree of radiation-induced remineralization in MM patients to gain a better understanding of its potential impact on bone mineral density and, consequently, fracture prevention. Our primary outcome measure was percent change in bone mineral density measured in Hounsfield Units (Δ% HU) between pre

Совпадение в полном тексте источника
… Retreatments Within 2 years following radiation therapy, a subset of our study cohort underwent subsequent treatments, including additional radiation therapy or surgical interventions. Of the analyzed patients, 15 (12.6%) received further treatment after the follow-up CT scan. …

Emerging Real-World Treatment Patterns and Clinical Outcomes of Multiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Study in the Private Healthcare Sector.

As treatments for multiple myeloma (MM) evolve, there is a need for real-world insights into treatment patterns and outcomes. The treatment practices and clinical outcomes in patients with MM (TOTEMM) was a database study (2018-2024) of newly diagnosed transplant-ineligible patients with MM in Argentina (TOTEMM-A) and Brazil (TOTEMM-B) in a private healthcare setting. In TOTEMM-A (n = 72) and TOTEMM-B (n = 892), 37 and 92 different drug regimens were reported, respectively. In each country, treatment duration reduced across lines of therapy (LOT) (TOTEMM-A: range, 6.2-3.4 months; TOTEMM-B: ran

Совпадение в полном тексте источника
… Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: A systematic literature review Front. Oncol. 2025 15 1550644 10.3389/fonc.2025.1550644 40144211 PMC11938063 36. Mateos M.-V. Weisel K. De Stefano V. Goldschmidt H. Delforge M. Mohty M. Cavo M. …

mTOR pathway as a potential therapeutic target for cancer stem cells in canine mammary carcinoma.

Mammary adenocarcinoma, the most common cancer in female dogs, often exhibits the lymph node and lung metastases and has a higher mortality rate. However, mammary adenocarcinoma has no established treatment, except early surgical excision. Canine mammary carcinoma has many common features with human mammary carcinoma, including clinical characteristics, heterogeneity, and genetic aberrations, making it an excellent spontaneous tumor model for human breast cancer. Diverse cancers comprised heterogeneous cell populations originating from cancer stem cells (CSCs) with self-renewal ability. Theref

Совпадение в полном тексте источника
… Velcade (Bortezomib) receives 2 new FDA indications: For retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma. Am Health Drug Benefits. (2015) 8:135–40. 73. …

Hematologic Malignancies: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.

OBJECTIVE: Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year. METHODS: Adults who met ClASsification criteria for Psoriatic ARthritis, with active disease (≥3 swollen and ≥3 tender joints; C reactive protein ≥0.3 mg/dL) despite standard treatment (31% previously received ≤2 tumour necrosis factor inhibitors (TNFi)), were randomised (1:1:1) to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at Week0, Week4, then Q8W; or placebo with cross-over to guselkumab

Совпадение в полном тексте источника
… Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE …

The Circular Life of Human CD38: From Basic Science to Clinics and Back.

Monoclonal antibodies (mAbs) were initially considered as a possible "magic bullet" for in vivo elimination of tumor cells. mAbs represented the first step: however, as they were murine in nature (the earliest experience on the field), they were considered unfit for human applications. This prompted the development of techniques for cloning the variable regions of conventional murine antibodies, genetically mounted on human IgG. The last step in this years-long process was the design for the preparation of fully human reagents. The choice of the target molecule was also problematic, since canc

Совпадение в полном тексте источника
… Considering the accessibility of ISA, which has recently been approved for therapy and features different functions, could this next-generation anti-CD38 mAb be considered for retreatment of DARA-refractory patients? …

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies1. Tumor complexity and heterogeneity suggest that the 'precision medicine' paradigm of cancer therapy requires treatment to be personalized to the individual patient2-6. To date, precision oncology trials have been based on molecular matching with predetermined monotherapies7-14. Several of these trials have been hindered by very low matching rates, often in the 5-10% range15, and low response rates. Low matching rates may be

PD-1 as a potential target in cancer therapy.

Recently, an improved understanding of the molecular mechanisms governing the host response to tumors has led to the identification of checkpoint signaling pathways involved in limiting the anticancer immune response. One of the most critical checkpoint pathways responsible for mediating tumor-induced immune suppression is the programmed death-1 (PD-1) pathway, normally involved in promoting tolerance and preventing tissue damage in settings of chronic inflammation. Many human solid tumors express PD ligand 1 (PD-L1), and this is often associated with a worse prognosis. Tumor-infiltrating lymp

Совпадение в полном тексте источника
… However, some patients who progressed after discontinuation of anti–PD-1 therapy have demonstrated durable responses after retreatment 47 . …

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal. Given its unique natural course, designing an ideal trial design for MG has been wrought with difficulties and evidence in favour of several of the conventional agents is weak as per current standards. Despite this, acetylcholinesterases and corticosteroids have remained the cornerstones of treatment for several decades with intravenous immuno

Совпадение в полном тексте источника
… Retreatment criteria required a 2-point reduction of MG-ADL from baseline. The primary endpoint was the proportion of MG-ADL responders (2-point reduction at each of 4 weeks starting from 1 week after the fourth dose) and was achieved by 68% on efgartigimod compared with 30% on placebo. … During the retreatment cycle, 71% of patients who received efgartigimod were responders. Amongst patients who did not respond after the initial treatment cycle, 37% responded after the second treatment cycle. …

Иммуноглобулиновые добавки и более длинные интервалы дозирования уменьшают риск инфицирования пациентов с ОРМ, обработанных теклистамбом.

Пациенты с реактивной/редактированной множественной миеломой (RRMM), которые проходят курс лечения с использованием диалектических антител (BSAbs) на базе BCMA, подвергаются повышенному риску инфицирования. Предыдущие исследования показали, что лечение иммуноглобулином внутривенно снижает риск серьезных инфекций. Однако вопрос о том, сокращает ли ИГИ инфекцию всех классов и имеет ли место воздействие более продолжительных интервалов дозирования на риск инфицирования, остается неизвестным. Для решения этой проблемы мы провели ретроспективное расследование 80 Пациенты с RRMM, которых лечили текл

Совпадение в полном тексте источника
… Recently, the patient experienced progression and did not respond to retreatment with teclistamab. …

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC).

Now, platinum-based chemotherapy is used as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Interestingly, a combination of immune checkpoint inhibitors, such as mepolizumab, with other targeted therapies and chemotherapy help to make a significant improvement. Atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1), blocks PD-1 activation and results in T-cell activity against tumor cells. As the second-line treatment of advanced or metastatic NSCLC, atezolizumab plus chemotherapy was

Совпадение в полном тексте источника
… Real-world efficacy of atezolizumab in non-small cell lung cancer: a multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thorac Cancer. 2021;12(5):613–8. 81. …

Страх рецидива рака у онкогематологических пациентов: инструменты оценки и основанные на фактических данных психологические меры - систематический обзор.

ВВЕДЕНИЕ: онкогематологические пациенты проходят сложный процесс эмоциональной адаптации, в рамках которого страх перед раком периодически возникает (ОКП). one из наиболее распространенных проблем. Этот страх не только негативно сказывается на их психологическом благополучии, но и связан со значительным снижением качества жизни. ЦЕЛЬ: Цель настоящего исследования заключается в проведении систематического обзора имеющихся доказательств в отношении: (1) факторы, связанные с FCR у онкогематологических пациентов.2) действительность и надежность инструментов, используемых для его оценки (см.3) тера

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.

ObjectivesThe current study aims to evaluate the safety and efficacy of anti-CD38 monoclonal antibodies (mAbs) among patients with relapsed/refractory multiple myeloma (RRMM) through meta-analysis.MethodsAs of June 2023, we searched PubMed, Web of Science, Embase and the Cochrane Library. Randomized controlled trials (RCTs) which compared the clinical outcomes of anti-CD38 mAbs plus immunomodulatory drugs (IMiDs) or proteasome inhibitors (PIs) plus dexamethasone and IMiDs (or PIs) and dexamethasone alone for RRMM patients were included. Efficacy outcomes were mainly evaluated with progression-

Совпадение в полном тексте источника
… Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma . Eur J Haematol ( 2023 ) 110 ( 6 ): 626–32 . doi: 10.1111/ejh.13942 36752328 47 Sonneveld P Broijl A . Treatment of relapsed and refractory multiple myeloma . …

Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy.

The treatment options for PsA have substantially expanded over the last decade. Approximately 40% of patients will not respond to first-line anti-TNF-α therapies. There is limited data to help clinicians select the most appropriate biologic therapy for PsA patients, including guidance for decisions on biologic therapy switching. In this review we will examine the current understanding of predictors of response to treatment. Imaging technology has evolved to allow us to better study psoriatic disease and define disease activity, including synovitis and enthesitis. Enthesitis is implicated in th

Совпадение в полном тексте источника
… Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE …

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.

Disruptive technologies, such as communicative reprogramming (anakoinosis) with cellular therapies in situ for treating refractory metastatic cancer allow patient care to accelerate along a totally new trajectory and highlight what may well become the next sea change in the care of patients with many types of advanced neoplasia. Cellular therapy in situ consisted of repurposed drugs, pioglitazone plus all-trans retinoic acid or dexamethasone or interferon-alpha (dual transcriptional modulation) combined with metronomic low-dose chemotherapy or low-dose 5-azacytidine, plus/minus classic targete

Совпадение в полном тексте источника
… 22 ], differing in the metronomically administered cytotoxic drug, capecitabine (CRPC I) versus treosulfan (CRPC II), and in an additional targeted therapy, imatinib (CRPC II); one published phase I part of an on-going phase II trial for multiple myeloma (MM, phase I, n = 6, > = third line therapy, retreatment …

Реальные результаты новых диагностированных пациентов из числа миеломы, лечившихся до эры Anti-CD38 Антитела: EMMY Cort 2017 в адрес 2020.

Последние агенты коренным образом изменили пейзаж миеломы (ММ). Их реальные последствия необходимо оценивать в долгосрочной перспективе. МЕТОДЫ: ЭММИ является неинтервенционной, перспективной динамичной когортой, осуществляемой во Франции, поскольку 2017, с 900 Пациенты ежегодно зачисляются в школу. Новый диагноз MM (NDMM) 2017 в адрес 2020 здесь описано. РЕЗУЛЬТАТЫ: Всего 1036 пациенты, имеющие право на нетрансплантацию (НПТ) (средний возраст: 74.9 годы) и 561 пациенты, получившие аутологическую трансплантацию стволовых клеток (ASCT) (средний возраст): 60.6 ), были зачислены. Для пациентов AC

Совпадение в полном тексте источника
… Macro , et al., “ Retreatment of Patients With Anti CD38‐Based Combinations in Multiple Myeloma in Real‐Life: Results From the Emmy Cohort Study ,” Blood 140 , no. Supplement 1 ( 2022 ): 7133 – 7135 . 10.1016/j.clml.2025.05.015 40518372 33 A. Perrot , O. Decaux , B. …

Vertebral Primary Bone Lesions: Review of Management Options.

The assessment and treatment of vertebral primary bone lesions continue to pose a unique yet significant challenge. Indeed, there exists little in the literature in the way of compiling and overviewing the various types of vertebral lesions, which can often have complicated intervention strategies. Given the severe consequences of mismanaged vertebral bone tumors-including the extreme loss of motor function-it is clear that such an overview of spinal lesion care is needed. Thus, in the following paper, we aim to address the assessment of various vertebral primary bone lesions, outlining the re

Совпадение в полном тексте источника
… This fact is significant as it confers SBRT an advantage over traditional open surgical techniques by allowing the treatment of tumors close to the spinal cord or at sites of retreatment while serving as a minimally invasive substitute [ 107 ]. …

Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?

Therapeutic repurposing emerged as an alternative to the traditional drug discovery and development model (DDD) of new molecular entities (NMEs). It was anticipated that by being faster, safer, and cheaper, the development would result in lower-cost drugs. As defined in this work, a repurposed cancer drug is one approved by a health regulatory authority against a non-cancer indication that then gains new approval for cancer. With this definition, only three drugs are repurposed for cancer: Bacillus Calmette-Guerin (BCG) vaccine (superficial bladder cancer, thalidomide [multiple myeloma], and p

Совпадение в полном тексте источника
… Only 10% of patients in whom treatment with propranolol was successful required systemic retreatment during follow-up. …